4.7 Article

Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding

期刊

JOURNAL OF MOLECULAR BIOLOGY
卷 433, 期 22, 页码 -

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2021.167242

关键词

BRD4; ASXL1; ET domain; ubiquitin; BAP1

资金

  1. Health Research Council of New Zealand

向作者/读者索取更多资源

Proper regulation of gene expression relies on specific protein-protein interactions between epigenetic regulators. Mutations in genes encoding these regulators, such as ASXL1, can lead to cancer and developmental disorders. This study provides a molecular mechanism for the interaction between ASXL1 and BRD4, showing that ASXL1 truncation enhances BRD4 recruitment to transcriptional complexes.
Proper regulation of gene-expression relies on specific protein-protein interactions between a myriad of epigenetic regulators. As such, mutation of genes encoding epigenetic regulators often drive cancer and developmental disorders. Additional sex combs-like protein 1 (ASXL1) is a key example, where mutations frequently drive haematological cancers and can cause developmental disorders. It has been reported that nonsense mutations in ASXL1 promote an interaction with BRD4, another central epigenetic regulator. Here we provide a molecular mechanism for the BRD4-ASXL1 interaction, demonstrating that a motif near to common truncation breakpoints of ASXL1 contains an epitope that binds the ET domain within BRD4. Binding-studies show that this interaction is analogous to common ET-binding modes of BRD4-interactors, and that all three ASX-like protein orthologs (ASXL1-3) contain a functional ET domain-binding epitope. Crucially, we observe that BRD4-ASXL1 binding is markedly increased in the prevalent ASXL1(Y591X) truncation that maintains the BRD4-binding epitope, relative to full-length ASXL1 or truncated proteins that delete the epitope. Together, these results show that ASXL1 truncation enhances BRD4 recruitment to transcriptional complexes via its ET domain, which could misdirect regulatory activity of either BRD4 or ASXL1 and may inform potential therapeutic interventions. (C) 2021 The Author(s). Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据